Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Celgene Corporation    CELG   US1510201049

CELGENE CORPORATION (CELG)

148
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

04/25/2013 | 08:25am US/Eastern
   By Ben Fox Rubin 
 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Order free Annual Report for Celgene Corp.

Visit http://djnweurope.ar.wilink.com/?ticker=US1510201049 or call +44 (0)208 391 6028

React to this article
Latest news on CELGENE CORPORATION
1d ago Stem Cell Therapy Market Poised to Reach $330 Million in 2020
3d ago CELGENE : Swissmedic Approves Revlimid
4d ago CELGENE : Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Ora..
5d ago CELGENE : Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals t..
11/18 CELGENE : Moffitt Cancer Center Announces Development of Experimental Treatment ..
11/18 CELGENE : Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two ..
11/17 Activist investor Elliott takes stake in Swiss firm BB Biotech
11/14 CELGENE : Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD..
11/13 CELGENE : Global Survey Finds That Pancreatic Cancer, a Leading Cause of Cancer ..
11/12 CELGENE : Data from More Than 160 Abstracts Highlighting Celgene Therapies to Be..
Advertisement
Chart
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF